(FY2025)

Performance

Revenue
¥201.7 billion Up 6.7% YoY ↑

Operating profit
¥15.9 billion Up 292.5% YoY ↑

ROE
5.9% Down 0.3 percentage point YoY ↓

ROIC
3.8% Down 0.5 percentage point YoY ↓

Ratio of equity attributable to owners of parent to total assets (Shareholders' equity to total assets)
49.6% Up 0.6 percentage point YoY ↑

Ratio of dividends to equity attributable to owners of parent (DOE)
3.6% Up 0.2 percentage point YoY ↑

Strengths

Production system ▶ p. 25
8 factories nationwide

Production capacity
20.5 billion tablets

Patents ▶ p. 29
78

Research and development expenses ▶ p. 29
¥12.4 billion

Quality assurance audits (GMP audits) ▶ p. 41
115

Number of MRs
Approx. 380

Social impact

Improving healthcare access

Sales volume
17.1 billion tablets

Share of prescription drug distribution volume in Japan
9.0%

Contributing to healthcare financing

Amount of reduction in healthcare costs
¥212.9 billion

Contributing to extension of healthy life expectancy

Personal health record (PHR) management app
Used by approx.
3,000 medical institutions